5] M), we judged the PBDEs and their metabolites to be positive for agonistic or antagonistic activity against that nuclear hormone receptor
Bile acids serve as metabolic integrators, activating major signaling pathways regulated by nuclear hormone receptors
including the farnesoid X receptor (FXR) and G protein-coupled receptors (GPCRs) such as TGR5.
Under the terms of the agreement, Invitrogen and PamGene will co-market Invitrogen's Nuclear Hormone Receptor
proteins and Lanthascreen(R) assay technology with PamGene's portfolio of microarray-based Nuclear Hormone Receptor
screening tools; specifically its PamChip(R) applications and PamStation(R) instrumentation.
New screening methods for chemicals with hormonal activities using interaction of nuclear hormone receptor
Glitazones appear to act primarily through the activation of nuclear hormone receptor
today announced that it has signed an extension of the company's research collaboration agreement with Bristol-Myers Squibb Company to develop and commercialize novel therapies targeted against the Liver X Receptor (LXR), a nuclear hormone receptor
implicated in a variety of cardiovascular and metabolic disorders.
We are excited to have the opportunity to build on Karo Bio's discoveries and expertise in the nuclear hormone receptor
field and to develop this important new class of drug.
PPAR gamma is the third nuclear hormone receptor
(NHR) available from ActiveSight for rapid co-crystal structure determination.
These new Portfolio targets expand a collection which includes the oncology targets Hsp90 and Aurora-A kinase; nuclear hormone receptor
targets PPAR-delta and FXR, implicated in metabolic disorders; PDE-4 for asthma and inflammation; the hypertension target Renin; the type-II diabetes target FBPase; and the anti-infective target bacterial DNA gyrase.
today announced that it signed a license agreement with Wyeth Pharmaceuticals, a division of Wyeth related to compounds targeting the farnesoid X receptor (FXR), a nuclear hormone receptor
implicated in a variety of metabolic and liver disorders.
The Locus approach was used to target nuclear hormone receptor
The Portfolio includes the oncology targets Hsp90 and Aurora-A kinase; nuclear hormone receptor
targets PPAR-delta and FXR, implicated in obesity; PDE-4 for asthma and inflammation; the hypertension target renin; the type-II diabetes target FBPase; and the anti-infective target bacterial gyrase.